1	Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated
2	malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda
3	Martin Kamilo Angwe ^{1,2,3*} , Norah Mwebaza ¹ , Sam Lubwama Nsobya ⁴ , Patrick Vudriko ² ,
4	Savior Dralabu ² , Denis Omali ^{1,5} , Maria Agnes Tumwebaze ² , Moses Ocan ¹
5	
6	¹ Department of Pharmacology and Therapeutics, College of Health Science, Makerere
7	University.
8	² Research Center for Tropical Diseases and Vector Control, Department of Pharmacy, Clinical
9	and Comparative Medicine, School of Veterinary Medicine and Animal Resources, College of
10	Veterinary Medicine, Animal Resources and Biosecurity, Makerere University.
11	³ Department of Biomolecular Resources and Biolab Sciences, School of Biosecurity,
12	Biotechnical and Laboratory Science, College of Veterinary Medicine, Animal Resources and
13	Biosecurity Makerere University
14	⁴ Infectious Diseases Research Collaboration, Makerere University.
15	⁵ Infectious Disease Institute, Makerere University.
16	
17	*Corresponding author
18	Email: martin.angwe@mak.ac.ug

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 Abstract

20 Artemisinin resistance threatens malaria control and elimination efforts globally. Recent 21 studies have reported the emergence of *Plasmodium falciparum* parasites tolerant to 22 artemisinin agents in sub-Saharan Africa, including Uganda. The current study assessed the 23 day 3 parasite clearance and its correlation with *P. falciparum K13* propeller gene (*pfkelch13*) mutations in P. falciparum parasites isolated from patients with uncomplicated malaria under 24 25 artemether-lumefantrine (AL) treatment. This study enrolled 100 P. falciparum-positive patients to whom AL was prescribed between 09/September/2022 and 06/November/2022. 26 27 Blood samples were collected in EDTA tubes before treatment initiation (day 0) and on day 3. 28 Parasitemia was assessed by microscopy from blood smears and quantitative polymerase chain 29 reaction (qPCR) from the DNA extracted. The day 0 parasite K13 gene was sequenced using 30 Sanger sequencing. Sequence data were analysed using MEGA version 11 software. The data 31 were analysed using STATA version 15, and the Mann-Whitney U test was used to compare 32 PCR parasite clearance on day 3 using the comparative CT value method and pfkelch13 33 mutations.

The prevalence of day 3 parasitaemia was 24% (24/100) by microscopy and 63% (63/100) by qPCR from the AL-treated patients. *P. falciparum K13*-propeller gene polymorphism was detected in 18.8% (15/80) of the day 0 DNA samples. The *K13* mutations found were C469Y, 12.5% (10/80); A675V, 2.5% (2/80); A569S, 1.25%, (1/80), A578S, 1.25%, (1/80) and; F491S, 1.25%, (1/80) a new allele not reported anywhere. The C469Y mutation, compared to the wildtype, was associated with delayed parasite clearance p=0.0278, Hodges-Lehmann estimation 3.2108 on the log scale, (95% CI 1.7076, 4.4730).

There was a high prevalence of day 3 *P. falciparum* among malaria patients treated using
artemether-lumefantrine. We conclude that the *K13* mutation associated with artemisinin

- 43 resistance by *P. falciparum* is present in Adjumani district, Uganda. This necessitates regular
- 44 surveillance of the effectiveness and efficacy of artemether-lumefantrine in the country.
- 45 Keywords: Artemether-lumefantrine, Day 3 parasitaemia, Artemisinin resistance, K13
- 46 *mutation, Plasmodium falciparum.*

47 Introduction

Malaria continues to pose a substantial global health challenge, with sub-Saharan Africa (SSA) 48 49 bearing the highest burden of the disease's impact. In 2022, the World Health Organization 50 (WHO) reported 249 million malaria cases worldwide, an increase of at least 5 million cases 51 compared to the previous year, with the WHO African region accounting for 94% of the cases 52 (1,2). Uganda contributes at least 5% of the worldwide malaria cases, most of which occur in 53 rural areas, especially in Northern and Eastern Uganda. There have been extensive control and 54 prevention interventions, such as the distribution of insecticide-treated bed nets (ITNs) 55 covering at least 82% of households in Uganda, indoor residual spraying (IRS) in some regions 56 being scaled up, and antimalarial medications. Despite these interventions, the area has 57 witnessed stagnation in malaria elimination efforts and an increase in malaria cases in Northern Uganda, highlighting the persistent challenge of malaria, especially in resource-limited settings 58 59 (3).

60 The current malaria treatment approach for uncomplicated *Plasmodium falciparum* infection 61 involves using artemisinin-based combination therapies (ACTs). Uganda adopted artemether-62 lumefantrine (AL) as a first-line therapy for uncomplicated *P. falciparum* malaria, which has been crucial in reducing malaria mortalities for almost two decades (1,4–6). These therapies 63 64 combine the short-acting artemisinin derivative (artemether) with another long-acting 65 antimalarial drug (lumefantrine), enhancing efficacy and reducing the risk of resistance 66 development. In addition to case management by the ACTs, control measures such as ITNs, 67 IRS, and malaria chemoprevention have been integral in reducing malaria transmission (7–12).

68 Despite these efforts, several challenges persist in the fight against malaria. Inadequate supply 69 of antimalarial medicines, especially in remote areas, often results in stockouts of ACTs, the 70 cornerstone of malaria treatment (13). Moreover, the proliferation of substandard antimalarial

agents and self-medication pose a significant public health risk, undermining treatment effectiveness and contributing to artemisinin resistance development (14,15). Artemisinin resistance, characterised by *Pfkelch*13 (*K*13) gene mutations (16) and delayed parasite clearance, has emerged as a serious concern, and molecular markers of artemisinin resistance have been identified in many SSA countries (17,18). Recent studies in Uganda reported the emergence of artemisinin resistance in the Eastern and Northern regions (19–21), a threat that is becoming evident to the effectiveness of artemisinin combination therapy.

78 The widespread development of artemisinin resistance could reverse the gains made in malaria 79 control and elimination, potentially leading to an increase in malaria morbidity and mortality. 80 This may lead to a similar catastrophic event previously observed when chloroquine was 81 withdrawn from malaria treatment due to widespread resistance (22,23). In Uganda, where 82 healthcare systems are often overburdened with limited access to quality healthcare (24,25), 83 the spread of artemisinin resistance could undermine decades of progress and investment in malaria control, and this could be worsen by the lack of effective alternatives to artemisinin 84 85 antimalarial agents in malaria treatment.

This study assessed the prevalence of day 3 *P. falciparum* in patients with uncomplicated malaria treated with AL and the prevalence of *K13*-propeller gene mutations associated with artemisinin resistance. The study's findings provide context-specific evidence on artemisinin resistance among *P. falciparum* parasites in patients treated using artemether-lumefantrine in the West Nile region, Uganda.

91 Materials and Methods

92 **Ethical statement.**

The protocol was reviewed, and ethical approval was obtained from the School of Biomedical Sciences Research and Ethics Committee at the College of Health Sciences, Makerere University (SBS-2022-157). Administrative clearance was obtained from Adjumani district authorities. Written informed consent was obtained from all participants before data collection, parental consent was obtained from participants aged 5-7 years, assent and parental consent were obtained from participants aged 8-17 years, and participants 18 years old and above consented to the study.

100 Study area

101 The study was conducted in the Adjumani district located in the West Nile region, northwest 102 of Uganda. The region neighbours the Democratic Republic of Congo and South Sudan. The 103 district is among the highest malaria endemic districts in the country, with malaria transmission 104 throughout the year and a prevalence reported above 50% by microscopy during the country's 105 malaria indicator survey (26).

106 Study design

107 This was a prospective longitudinal study which recruited malaria patients between 108 09/September/2022 and 06/November/2022 receiving artemether-lumefantrine (AL) 20 mg 109 artemether/120 mg lumefantrine tablets, 3-day six-dose regimen prescribed according to 110 patient weight for treatment of uncomplicated malaria at Adjumani District Hospital. Blood 111 samples were collected from the patient on day 0 (before drug intake) and day 3 (after 112 treatment). The study enrolled 100 purposively selected uncomplicated malaria patients aged 113 five years and above with confirmed *P. falciparum* infection. A study purpose non-validated questionnaire was used to collect information on the socio-demographic characteristics of the patients, including age, gender, and previous history of malaria treatment. The study collected both patient socio-demographic and laboratory data. *Plasmodium falciparum* parasite infections among symptomatic malaria patients were determined using microscopy and qPCR from the College of Veterinary Medicine Animal Resources and Biosecurity, Pharmacology/Research Center for Tropical Diseases and Vector Control, and Central Diagnostic Laboratory.

121 **Blood sample collection.**

Venous blood (2-3ml) was collected in an EDTA tube. Two blood samples were collected from
each patient; the first was on day 0, before initiation of treatment, and the second was collected
on day 3, after completion of artemether-lumefantrine therapy.

125 Microscopy

On days 0 and 3, thick and thin smears were prepared for detection and speciation of *Plasmodium falciparum* infection, respectively. The blood smears were stained with 10% Giemsa stain for 30 minutes, then examined using an Olympus microscope under 100X magnification with oil immersion to identify the parasite and determine the parasite density. Two independent microscopists/laboratory technologists examined the slides for *P. falciparum* confirmation and enumeration.

132 **DNA extraction**

133 The parasite DNA was extracted using a Qiagen DNA mini kit (QIAamp DNA Blood Mini 134 Kit-250, Germany), following the manufacturer's instructions. Elution was performed in 50 μ L 135 elution buffer, and the DNA concentration was determined (25-40 ng/ μ l) using NanoDrop 136 (NanoDrope Lite Plus, thermo scientific) before PCR amplification.

137 Plasmodium falciparum qPCR

Quantitative PCR (qPCR) was performed using a real-time PCR system (QuantStudioTM5) to detect and quantify the *Plasmodium falciparum* in duplicate. Primers and probes were based on the 18S rRNA sequence (27) synthesised from Inqaba Biotec Laboratory, South Africa. The amplification followed a method in a previous study (28). The CT values were recorded and used to calculate parasite clearance through fold change, $2^{-\Delta\Delta CT}$ by a comparative CT value method (29). The method considered two data points of CT values at day 0 and day 3 for individuals that remained positive on day 3.

145 Specific primers were used for the qPCR (Table 1); the probe was labelled with 5'FAM (6carboxyfluorescein) and BHQ-1TM (Black Hole Quencher) as the reporter and quencher, 146 147 respectively. 20 µl reaction volume was prepared, composed of 0.8 µl of each forward and 148 reverse primer, 10 µl of qPCR master mix (Luna Universal Probe qPCR Master Mix NEB, 149 New England BioLabs Inc), 0.4 µl of the probes, 20 ng of the DNA template and nuclease-150 free water (variable). The PCR conditions involved one cycle at 94°C for 5 min of initial 151 denaturation, followed by 40 cycles of denaturation at 94°C for 30 s, annealing at 54°C for 90 s and extension at 68°C for 90 s, and a final extension at 68°C for 90 s. 152

153 *P. falciparum K13* allele

154 Conventional nested PCR was performed (SimpliAmp Thermal Cycler, applied biosystem) to 155 amplify approximately 800 bp fragment that extends from nucleotides position 1329-to-2178 156 (codons 445-to-727) within the propeller domain of the *K13* gene using the specific primers 157 (16) Table 1.

PCR	Primers	Sequence
Nested PCR	K131/K13_PCR-F	5'CGGAGTGACCAAATCTGGGA-3'
	K134/K13_PCR_R	5'-GGGAATCTGGTGGTAACAGC-3'
	K132/K13_N1_F	5'GCCAAGCTGCCATTCATTTG-3'
	K133/K13_N1_R	5'-GCCTTGTTGAAAGAAGCAGA-3'
qPCR	Forward	5'-GCTCTTTCTTGATTTCTTGGATG-3
	Reverse	5'-AGCAGGTTAAGATCTCGTTCG-3'.
	Probe	5'-ATGGCCGTTTTTAGTTCGTG-3'

158 Table 1: Primer sequences used for nested PCR and qPCR

159

160 *P. falciparum K13* gene amplification

The first round PCR was performed in a 25 µl reaction volume of 12.5 µl OneTag 2X Master 161 Mix (NEB, New England BioLabs Inc), 1 µl of each forward and reverse primer and 2.5 ng 162 of the DNA template and nuclease-free water (variable). The PCR was run with the following 163 conditions: 94°C for 5 m initial denaturation, 40 cycles at 94°C for 30 s, annealing at 54°C for 164 90 s, and extension at 68°C for 90 s. The final extension was performed at 68°C for 10 minutes, 165 166 then kept at 4°C, which was set to infinite. The amplicon from the first round of PCR was used 167 as a template for the second round. This was run in a 25 µL reaction mixture volume; it involved 168 the same master mix preparation as the first run, but the second primer sets were used with 1 169 µl of the first PCR product/amplicon. The PCR product was visualised using gel electrophoresis run at 100 V for 30 minutes in 1.5% agarose stained with 0.05 µg/mL Acridine 170 orange (SafeView Classic). 171

172 Amplicon preparation and cleaning

173 The nested PCR products were cleaned using ExoSAP. The Exo/SAP master mix was prepared 174 by adding 50 μ L of exonuclease I (Catalogue No. NEB M0293) 20 U/ μ l and 200 μ l of shrimp 175 alkaline phosphatase (Catalogue No. NEB M0371) 1 U/ μ l to a 0.6 ml microcentrifuge tube. 176 Then, 2.5 μ l of the ExoSAP mixture was mixed with 10 μ L of the amplicon/PCR product and 177 incubated at 37°C for 15 min; the reaction was stopped by heating the mixture at 80°C for 15

178 min.

179 Plasmodium falciparum K13 Sequencing

The nested PCR products were sequenced using the Nimagen BrilliantDyeTM Terminator Cycle Sequencing kit V3.1, BRD3-100/1000, according to the manufacturer's instructions at the Inqaba Biotec laboratory in South Africa, a commercial sequencing company. The labelled product was then cleaned with a ZR-96 DNA sequencing clean-up Kit (Catalogue No. D4053). The cleaned product was injected into an Applied Biosystems ABI 3730XL Genetic Analyser with a 50 cm array using POP7. Sequence chromatogram analysis was performed using FinchTV analysis software.

187 Data management and analysis

The K13 sequence qualities were assessed, and then BLAST against the NCBI database to 188 189 confirm the identity of the gene sequence. After exporting the sequence into the Bioedit 190 sequence alignment editor, manual editing was performed, and the sequence was exported into 191 MEGA11 software for polymorphism detection using the sequence *PF3D7* 1343700 from the 192 NCBI database as the reference sequence. Sequence alignment was performed using the 193 ClustalW algorithm, and a phylogenetic tree was drawn using MEGA11 Tree Explorer to 194 identify divergence in the *P. falciparum K13* genes and identify the mutations. Data were 195 entered in Excel and analysed in STATA version 17; CT value fold change from the qPCR data

- 196 was log-transformed before correlation. The relationship between the CT value fold change
- 197 related to parasite clearance and *K13* mutation was determined through a nonparametric test
- 198 (Mann-Whitney U test) with a 95% confidence interval and level of significance set at p < 0.05.
- 199 **Results**
- 200 Characteristics of the study participants
- 201 The study included 100 symptomatic uncomplicated malaria patients, of which the majority,
- 202 65% (65/100), were females. The mean age of the study participants was 17±10 years, ranging
- from 5 to 46 years. Parasitemia/µl geometric mean by microscopy was 3868, IQR 11104 for
- all patients.

205 Prevalence of *P. falciparum* on day three after AL treatment

- 206 *P. falciparum* parasites persisted in 24% (24/100; 95%CI: 16-33) of the participants screened
- using microscopy, whereas by PCR, the parasites were found in over half, 63% (63/100;
- 208 95%CI: 53-72) on day 3 following artemether-lumefantrine treatment (Table 2).

210	Table 2: Day 3 P.	falciparum	positivity	distribution among	the different age groups.
	•	.		0	

Characteristics	Microscopy and PCR	Day 3 positivity				
	positive, day 0 (N=100)	Microscopy, n (%)	PCR n (%)			
Age						
5-12	35	10 (28.57)	23 (65.71)			
13-18	37	9 (24.32)	24 (64.86)			
19 and above	28	5 (17.86)	16 (57.14)			
Sex						
Male n=35	35	7 (20.00)	22 (62.86)			
Female n=65	65	17 (26.15)	41 (63.08)			
otal Participants	100	24 (24.00)	63 (63.00)			

212 N=number of participants; n=number of participants who remained positive on day 3

213

214 Prevalence of *Pfkelch13* Single nucleotide polymorphism (SNPs)

215 A total of 80 samples (amplicons) out of the 100 were successfully sequenced for K13 Single 216 Nucleotide Polymorphism (SNP) identification. Of the 80 sequenced samples, 24/80 were the 217 day 3 microscopy positive, and 58/80 were day 3 PCR positive samples; the 20/100 218 unsequenced samples contain 5/20 day 3 qPCR positive samples, but all microscopy negative 219 (20/20). K13 SNPs were detected in 18.8% (15/80; 95%CI: 11.25-27.5) of the P. falciparum 220 parasite samples sequenced (Table 3). All the K13 SNPs were nonsynonymous mutations. The 221 most prevalent nonsynonymous K13 SNP was C469Y, at 12.5% (10/80; 95%CI: 6.25-20). 222 Other K13 SNPs in the P. falciparum parasites were A675V (2.25%, 2/80; 95%CI: 0.0-6.25), 223 A569S (1.25%, 1/80; 95%CI:0.0-3.75) and A578S (1.25%, 1/80; 95%CI: 0.0-3.75). One 224 mutation not previously reported was detected in one sample where amino acid F was 225 substituted by S at codon 491 in the *K13* propeller domain, involving a nucleotide change from 226 T to C at position 1472.

228									
	Mutations	Wild-type amino acid	Mutant amino acid	Codon position	Wild-type nucleotide	Mutant nucleotide	Mutation type	Nucleotide position	Prevalence (n=80)
	C469Y ^{ab}	Cysteine	Tyrosine	469	G	А	NS	1406	12.50% (n=10)
	A675V ^{ab}	Alanine	Valine	675	С	Т	NS	2024	2.50% (n=2)
	A569S ^a	Alanine	Serine	569	G	Т	NS	1705	1.25% (n=1)
	A578S ^a	Alanine	Serine	578	G	Т	NS	1732	1.25% (n=1)
	F491S	Phenylalanine	Serine	491	Т	С	NS	1491	1.25% (n=1)

227 Table 3: Prevalence of *K13* single-nucleotide polymorphisms in *P. falciparum* parasites among patients in Adjumani District.

229 NS=non synonymous mutation; n=number of samples sequenced; ^aPreviously reported *K13* allele, ^{ab}Candidate for artemisinin resistance

Relationship between day 3 *P. falciparum* clearance and *Pfkelch13* Single nucleotide polymorphism.

232 Eight (8/10) patients with parasites with C469Y and one (1/1) patient with the A578S P. 233 falciparum K13 mutation remained positive on day three by PCR. By microscopy, 5/10 patients 234 with *P.falciparum* having C469Y and 1/1 having A578S remained positive on day 3 (Table 4). 235 A comparison of the parasite clearance between the wild-type, median parasite fold reduction 236 522, 7043 (median, IQR) and mutated K13 parasites showed significantly low parasite 237 clearance in C469Y, median fold reduction 14, 792 (Median, IQR) and A578S, fold reduction 1.6. Among the day 3 qPCR-positive *P. falciparum* patients, those with the C469Y mutated *P.* 238 239 *falciparum* demonstrated low parasite clearance compared to the wild-type *p*=0.0278, Hodges-240 Lehmann estimation 3.2108 on the log scale (95% CI 1.7076, 4.4730). Parasitemia/µl geometric 241 mean for patients with wild-type P. falciparum 65/80 was 3795, IQR 10589, while that for the

patients with C469Y P. falciparum (10/80) was 3373, IQR 26099 for the sequenced samples.

242

Table 4: Day 3 positivity and CT value fold change in the K13 alleles from the parasites sequenced

				CT value fold change/Parasite
	Initial parasitemia	Day 3 J	positivity	clearance
K13 allele	Geo mean (IQR)	Microscopy	PCR	Median (IQR)
Wild-type, n=65	3794.954 (10588.5)	18	49	522 (7043)
C469Y, n=10	3373.35 (26099.5)	5	8	14 (792)
A675V, n=2	1578, 25651	0	0	-
A569S, n=1	27651	0	0	-
A578S, n=1	1782	1	1	1.6
F491S, n=1	8544	0	0	-
A569S, n=1 A578S, n=1 F491S, n=1	27651 1782 8544	0 1 0	0 1 0	- 1.6 -

245 **Discussion**

Artemether-lumefantrine (AL), the first-line treatment for uncomplicated malaria in Uganda, at the current standard fixed weight-based dose regimen, has been pivotal in reducing malariarelated morbidity and mortality. However, emerging *P. falciparum K13* mutations associated with reduced *P. falciparum* susceptibility to AL threaten malaria control and elimination efforts in sub-Saharan Africa. Reduced susceptibility to AL that may be characterised by the persistence of the parasite on day 3 could be associated with partial artemisinin resistance.

252 Our study reports that, on day 3, there was a prevalence of 24% *P. falciparum* by microscopy 253 among the patients treated with AL in Adjumani district, Northern Uganda. This could indicate 254 the emergence of partial artemisinin resistance. We observed a high prevalence of P. 255 *falciparum* parasites by microscopy, 24% and quantitative polymerase chain reaction (qPCR), 256 63%, after three days of AL treatment. This observation aligns with previous studies that have 257 reported similar persistence of parasites beyond the standard three-day treatment period in 258 Africa and elsewhere (30–33). Equally, our qPCR results indicated a prevalence of 63%, 259 consistent with a study by Tadele et al. (28) that reported a 60% PCR prevalence of day three 260 P. falciparum parasites among patients treated with AL, which may not be sufficient to indicate the development of partial artemisinin resistance. However, the 24% prevalence by microscopy 261 262 could be a pointer to the potential emergence of partial P. falciparum resistance against AL, 263 the current cornerstone of malaria treatment. WHO advises that a day-three parasitemia in 264 patients on ACT treatment calls for routine monitoring to identify suspected artemisinin partial 265 resistance in *P. falciparum* (34).

The persistence of *P. falciparum* parasites on day 3 raises a concern regarding the current effectiveness of artemether and the efficacy of the AL regimen. Our study found a 24% microscopy positivity for *P. falciparum* on day three, which could indicate a possible

269 emergence of partial artemisinin resistance (35,36). A similar finding on the persistence of P. 270 falciparum has been reported previously in AL-treated malaria patients in Uganda (30,37–39). 271 Whether this is attributed to the development of resistance, especially the K13 mutation, or lack 272 of adherence to AL has not been fully established. However, a previous study in Uganda has demonstrated moderate to high adherence to AL in treating uncomplicated malaria, whether 273 274 taken under supervision or not (40). Day 3 positivity and residual *P. falciparum* are likely to 275 cause an increase in malaria recurrence and transmission to female Anopheles mosquitoes (41), 276 driving infection to people and jeopardising the gain in malaria control.

277 The study identified nonsynonymous mutations at codons 469, 675, 569, 578 and 491 of the 278 K13 propeller gene. This mutation pattern is consistent with recent findings in Uganda 279 (20,39,42–44). The codons 469 and 675 mutations have been associated with artemisinin 280 resistance in northern Uganda (19,21). This is consistent with our finding that most patients 281 with C469Y-mutated P. falciparum had parasites that persisted after three days of AL 282 treatment. Among the K13 mutations identified, patients carrying parasites with C469Y (5/10) 283 and A578S (1/1) mutations remained microscopy-positive on day 3; similarly, qPCR results 284 showed high day 3 positivity (8/10) for the C469Y. Unlike a study by Stoke et al. (45) that did 285 not link the C469Y mutation with parasite resistance or delay in parasite clearance, in this 286 study, C469Y was associated with low parasite fold reduction 14, 792 (median, IQR), 287 compared to the wild-type, an indication of reduced *P. falciparum* clearance. This is consistent 288 with the findings of Balikagala et al. and Tumwebaze et al. (19,21) that demonstrated delayed 289 parasite clearance and resistance. A similar study in Pakistan reported a high association 290 between C469Y and artemisinin resistance (46). Among the patients with *P. falciparum* that 291 remained positive on day 3, we identified one patient (1/1) with A578S mutated parasite having 292 a low parasite fold reduction of 1.6. The A578S mutation has been sporadically reported in 293 sub-Saharan African countries (20,47–49), and a study in Uganda reported some association

between A578S and slow parasite clearance (50), contrary to studies elsewhere that could not
associate it with artemisinin resistance (51,52).

296 The prevalence of mutation at codon 675 in the malaria patients was 2.5%, and none of the 297 patients with parasites having the A675V mutation remained *P. falciparum* positive on day 3. 298 Although the A675V mutation was previously associated with resistance in Northern Uganda 299 (19), our current study could not link the few to the persistence of *P. falciparum* on day 3, 300 possibly due to the low prevalence and likelihood of chance finding that they are not positive 301 on day 3. Although the A675V mutation is a candidate mutation for artemisinin resistance, a 302 study by Tumwebaze et al. and Stoke et al. (21,45) reported high parasite clearance among 303 parasites with the A675V mutations. We also identified a mutation at codon position 491, 304 which had previously not been identified anywhere. This finding shows the existence of a 305 reservoir for K13 propeller gene polymorphisms, not only in Uganda but also globally in 306 malaria-endemic places (53,54). The diversity of K13 propeller gene mutations across regions 307 further emphasises the need for continued surveillance and research to understand their 308 implications in artemisinin resistance.

309 Our study had some limitations. Firstly, parasites detected on day 3 were not confirmed 310 whether they were the same parasite on day 0 or a newly acquired infection. Secondly, we did 311 not confirm adherence to treatment among malaria patients who participated in the study. 312 Third, the parasite load on day 0 was not the same across all the patients; low and high P. 313 falciparum infections were all considered; the study considered P. falciparum positive patients 314 with no specific parasite load and as long as they were prescribed AL. Fourth, the study used 315 two data points of day 0 and day 3 to determine the parasite clearance through fold changes; 316 this makes the data less likely to precisely establish the linear correlation of the parasite 317 clearance slope and unable to capture the fold change pattern of those who are negative on day 318 3. Lastly, the clinical outcome of the participants was not evaluated according to the WHO 28-319 day recommendation for an efficacy study. However, the limitations were unlikely to 320 significantly affect the study's outcome in determining artemisinin effectiveness and 321 identifying markers of artemisinin resistance. Future studies should consider using multiple 322 data points when using the CT value method to assess parasite clearance in effectiveness and 323 efficacy studies of artemisinin.

324 Conclusion

The day 3 prevalence of 24% *P. falciparum* by microscopy in the AL-treated patients could indicate the presence of partial resistance to artemisinin. There is an increase in the prevalence of K13 mutation associated with resistance, especially the C469Y, which is associated with a low-fold change in parasite reduction. There is a need to re-evaluate the effectiveness of artemisinin agents in malaria treatment and ensure continuous monitoring of their efficacy in Uganda.

331 Acknowledgement

We acknowledge the research participants from Adjumani Hospital, the staff of Adjumani Hospital: Mr Amosu Emmanuel (Laboratory Technologist), Mr Iranya Vincent (Clinical Officer), Mr Amaruma Allan Levi (Clinical Officer), and Mr Anyanzo Ben (Community Health Worker). Colleagues at Pharmacology/Research Center for Tropical Disease and Vector Control (RTC) laboratory and Central Diagnostic Laboratory.

337 Funding

This study was supported by funding through the EDCTP2 programme supported by the European Union (TMA2019CDF-2662-Pfkelch13 emergence) and Fogarty International Center of the National Institute of Health under award number 1R25TW011213. The content

- is solely the responsibility of the authors and does not necessarily represent the official view
- 342 of the EDCTP and the National Institute of Health.

343 Authors Contributions

- 344 Conceived and designed the study: MKA MO NM SLN. Performed the experiments: MKA DS
- 345 MAT. Analysed the data: MKA MO NM. Contributed reagents/materials/analysis tools: MKA
- 346 MO VP. Initial drafting of manuscript: MKA. Contributed to the final writing of the
- 347 manuscript: MKA MO NM SLN DS OD VP MAT.

348

349 Kelerences	349	References
-----------------------	-----	------------

- 1. Health Organization W. World malaria report 2022 [Internet]. Available from:
- 351 https://www.who.int/teams/global-malaria-programme
- Health Organization W. World malaria report 2022 [Internet]. 2023. Available from:
 https://www.wipo.int/amc/en/mediation/
- The Republic of Uganda Ministry of Health. Uganda Malaria Indicator Survey 2018 2019. 2020.
- 356 4. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, et al. Artemisinin
- 357 Combination Therapies for Treatment of Uncomplicated Malaria in Uganda. 2006;
- 358 Available from: www.plosclinicaltrials.org
- 359 5. Sarah G Staedke, Arthur Mpimbaza, Moses R Kamya, Bridget K Nzarubara, Grant
- 360 Dorsey, Philip J Rosenthal. Combination treatments for uncomplicated falciparum
- 361 malaria in Kampala, Uganda: randomised clinical trial [Internet]. Available from:

362 www.thelancet.com

- 363 6. Organization WH. Guidelines for the treatment of malaria. World Health Organization;
 364 2015.
- Nankabirwa JI, Arinaitwe E, Rek J, Kilama M, Kizza T, Staedke SG, et al. Malaria
 transmission, infection, and disease following sustained indoor residual spraying of
 insecticide in Tororo, Uganda. American Journal of Tropical Medicine and Hygiene.
 2020 Oct 1;103(4):1525–33.
- 369 8. Oguttu DW, Matovu JKB, Okumu DC, Ario AR, Okullo AE, Opigo J, et al. Rapid
 370 reduction of malaria following introduction of vector control interventions in Tororo
- 371 District, Uganda: a descriptive study. Malar J. 2017;16(1):1–8.
- 372 9. Katureebe A, Zinszer K, Arinaitwe E, Rek J, Kakande E, Charland K, et al. Measures
- 373 of Malaria Burden after Long-Lasting Insecticidal Net Distribution and Indoor
- 374 Residual Spraying at Three Sites in Uganda: A Prospective Observational Study. PLoS
 375 Med. 2016 Nov 1;13(11).
- 10. Kwambai TK, Dhabangi A, Idro R, Opoka R, Watson V, Kariuki S, et al. Malaria
- 377 Chemoprevention in the Postdischarge Management of Severe Anemia. New England
 378 Journal of Medicine. 2020 Dec 3;383(23):2242–54.
- 11. Tumwebaze P, Conrad MD, Walakira A, LeClair N, Byaruhanga O, Nakazibwe C, et
- al. Impact of antimalarial treatment and chemoprevention on the drug sensitivity of
- 381 malaria parasites isolated from Ugandan children. Antimicrob Agents Chemother.
- 382 2015;59(6):3018–30.
- 383 12. Plowe C V. Malaria chemoprevention and drug resistance: a review of the literature
 384 and policy implications. Vol. 21, Malaria Journal. BioMed Central Ltd; 2022.
- Batwala V, Magnussen P, Nuwaha F. Challenges to implementation of artemisinin
 combination therapy policy in Uganda. Int Health. 2010 Dec;2(4):262–8.

387	14.	Ocan M, Nakalembe L, Otike C, Omali D, Buzibye A, Nsobya S. Pharmacopeial
388		quality of artemether-lumefantrine anti-malarial agents in Uganda. Malar J.
389		2023;22(1):1–11.
390	15.	Ocan M, Obuku EA, Bwanga F, Akena D, Richard S, Ogwal-Okeng J, et al.
391		Household antimicrobial self-medication: a systematic review and meta-analysis of the
392		burden, risk factors and outcomes in developing countries. BMC Public Health.
393		2015;15:1–11.
394	16.	Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A
395		molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature.
396		2014;505(7481):50–5.
397	17.	Uwimana A, Legrand E, Stokes BH, Ndikumana JLM, Warsame M, Umulisa N, et al.
398		Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium
399		falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26(10):1602-
400		8.
401	18.	Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al.
402		Association of Plasmodium falciparum kelch13 R561H genotypes with delayed
403		parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic
403 404		parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021 Aug 1;21(8):1120–8.
403 404 405	19.	parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021 Aug 1;21(8):1120–8. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al.
403404405406	19.	parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021 Aug 1;21(8):1120–8. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. New England Journal of Medicine.
 403 404 405 406 407 	19.	parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021 Aug 1;21(8):1120–8. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. New England Journal of Medicine. 2021;385(13):1163–71.
 403 404 405 406 407 408 	19. 20.	parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021 Aug 1;21(8):1120–8. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. New England Journal of Medicine. 2021;385(13):1163–71. Asua V, Conrad MD, Aydemir O, Duvalsaint M, Legac J, Duarte E, et al. Changing
 403 404 405 406 407 408 409 	19. 20.	parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021 Aug 1;21(8):1120–8. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. New England Journal of Medicine. 2021;385(13):1163–71. Asua V, Conrad MD, Aydemir O, Duvalsaint M, Legac J, Duarte E, et al. Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin

|--|

- 412 Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and
- 413 lumefantrine in northern Uganda. Nat Commun. 2022;13(1).
- 414 22. Kamya MR, Bakyaita NN, Talisuna AO, Were WM, Staedke SG. Increasing
- 415 antimalarial drug resistance in Uganda and revision of the national drug policy. Vol. 7,
- 416 Tropical Medicine and International Health. 2002. p. 1031–41.
- 417 23. Sendagire H, Kaddumukasa M, Ndagire D, Aguttu C, Nassejje M, Pettersson M, et al.
- 418 Rapid increase in resistance of Plasmodium falciparum to chloroquine-Fansidar in
- 419 Uganda and the potential of amodiaquine-Fansidar as a better alternative. Acta Trop.

420 2005 Sep;95(3):172–82.

- 421 24. Dowhaniuk N. Exploring country-wide equitable government health care facility
 422 access in Uganda. Int J Equity Health. 2021 Dec 1;20(1).
- 423 25. Rahimi A, Kassam R, Dang Z, Sekiwunga R. Challenges with accessing health care
- 424 for young children presumed to have malaria in the rural district of Butaleja, Uganda:

425 A qualitative study. Pharm Pract (Granada). 2019;17(4).

- 426 26. National Malaria Control Division (NMCD) & Uganda Bureau of Statistics (UBOS).
- 427 2018-19 Uganda Malaria Indicator Survey (UMIS) Atlas of Key Indicators. 2018;
- 428 Available from: https://dhsprogram.com/pubs/pdf/ATR21/ATR21.pdf
- 429 27. Kamau E, Tolbert LDS, Kortepeter L, Pratt M, Nyakoe N, Muringo L, et al.
- 430 Development of a highly sensitive genus-specific quantitative reverse transcriptase
- 431 real-time PCR assay for detection and quantitation of plasmodium by amplifying RNA
- 432 and DNA of the 18S rRNA genes. J Clin Microbiol. 2011 Aug;49(8):2946–53.
- 433 28. Tadele G, Jaiteh FK, Oboh M, Oriero E, Dugassa S, Amambua-Ngwa A, et al.
- 434 Persistence of Residual Submicroscopic P. falciparum Parasitemia following

- 435 Treatment of Artemether-Lumefantrine in Ethio-Sudan Border, Western Ethiopia.
- 436 Antimicrob Agents Chemother. 2022 Sep 1;66(9).
- 437 29. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT
- 438 method. Nat Protoc. 2008 May;3(6):1101–8.
- 439 30. Betson M, Sousa-Figueiredo JC, Atuhaire A, Arinaitwe M, Adriko M, Mwesigwa G, et
- 440 al. Detection of persistent Plasmodium spp. infections in Ugandan children after
- 441 artemether-lumefantrine treatment. Parasitology. 2014 Dec 12;141(14):1880–90.
- 442 31. Mhamilawa LE, Ngasala B, Morris U, Kitabi EN, Barnes R, Soe AP, et al. Parasite
- 443 clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an
- 444 extended 6-day treatment of artemether-lumefantrine and a single low-dose
- 445 primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district,

446 Tanzania: A randomized controlled trial. Malar J. 2020;19(1).

- 447 32. Mwaiswelo R, Ngasala B, Jovel I, Xu W, Larsson E, Malmberg M, et al. Prevalence of
- 448 and Risk Factors Associated with Polymerase Chain Reaction-Determined
- 449 Plasmodium falciparum Positivity on Day 3 after Initiation of Artemether–
- 450 Lumefantrine Treatment for Uncomplicated Malaria in Bagamoyo District, Tanzania.
- 451 American Journal of Tropical Medicine and Hygiene. 2019;100(5).
- 452 33. Vreden SGS, Jitan JK, Bansie RD, Adhin MR. Evidence of an increased incidence of
- 453 day 3 parasitaemia in Suriname: An indicator of the emerging resistance of
- 454 Plasmodium falciparum to artemether. Mem Inst Oswaldo Cruz. 2013;108(8):968–73.
- 455 34. Health Organization W. Artemisinin resistance and artemisinin-based combination
- 456 therapy efficacy (Status report -- August 2018) [Internet]. 2018 [cited 2024 Apr 5].
- 457 Available from: http://apps.who.int/iris/bitstream/handle/10665/274362/WHO-
- 458 CDSGMP-2018.18- eng.pdf?sequence=1&isAllowed=y

459	35.	Ahorhorlu SY.	Ouashie N Ben	. Jensen RW. Kudz	i W. Narte	v ET. Duah-O	Duashie NO.
		,		,		/ ,	

- 460 et al. Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates
- 461 in children with uncomplicated malaria in Ghana. Malar J. 2023;22(1).
- 462 36. Wu Y, Soe MT, Aung PL, Zhao L, Zeng W, Menezes L, et al. Efficacy of artemether-
- 463 lumefantrine for treating uncomplicated Plasmodium falciparum cases and molecular
- 464 surveillance of drug resistance genes in Western Myanmar. Malar J. 2020;19(1).
- 465 37. Maniga JN, Akinola SA, Odoki M, Odda J, Adebayo IA. Limited polymorphism in
- 466 plasmodium falciparum artemisinin resistance kelch13-propeller gene among clinical
- 467 isolates from bushenyi district, uganda. Infect Drug Resist. 2021;14:5153–63.
- 468 38. Yeka A, Wallender E, Mulebeke R, Kibuuka A, Kigozi R, Bosco A, et al. Comparative
- 469 efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the
- 470 treatment of uncomplicated malaria in Ugandan children. Journal of Infectious
- 471 Diseases. 2019 Mar 15;219(7):1112–20.
- 472 39. Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, et al.
- 473 Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for
- 474 the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of
- 475 molecular markers associated with artemisinin and partner drug resistance in Uganda.
- 476 Malar J. 2021 Dec 1;20(1).
- 40. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, et al. Supervised
 versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute,
 uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised
 trial. The Lancet. 2005;365(9469):1467–73.
- 481 41. Beshir KB, Sutherland CJ, Sawa P, Drakeley CJ, Okell L, Mweresa CK, et al. Residual
 482 Plasmodium falciparum parasitemia in kenyan children after artemisinin-combination

26

483		therapy is associated with increased transmission to mosquitoes and parasite
484		recurrence. Journal of Infectious Diseases. 2013 Dec 15;208(12):2017-24.
485	42.	Asua V, Vinden J, Conrad MD, Legac J, Kigozi SP, Kamya MR, et al. Changing
486		molecular markers of antimalarial drug sensitivity across Uganda. Antimicrob Agents
487		Chemother. 2019;63(3).
488	43.	Tumwebaze P, Tukwasibwe S, Taylor A, Conrad M, Ruhamyankaka E, Asua V, et al.
489		Changing antimalarial drug resistance patterns identified by surveillance at three sites
490		in Uganda. Journal of Infectious Diseases. 2017 Feb 15;215(4):631-5.
491	44.	Conrad MD, Asua V, Garg S, Giesbrecht D, Niaré K, Smith S, et al. Evolution of
492		Partial Resistance to Artemisinins in Malaria Parasites in Uganda. New England
493		Journal of Medicine. 2023 Aug 24;389(8):722-32.
494	45.	Stokes BH, Ward KE, Fidock DA. Evidence of artemisinin-resistant malaria in Africa.
495		N Engl J Med. 2022;386(14):1385.
496	46.	Ghanchi NK, Qurashi B, Raees H, Beg MA. Molecular surveillance of drug resistance:
497		Plasmodium falciparum artemisinin resistance single nucleotide polymorphisms in
498		Kelch protein propeller (K13) domain from Southern Pakistan. Malar J. 2021 Dec
499		1;20(1).
500	47.	Maïga-Ascofaré O, May J. Is the A578S single-nucleotide polymorphism in K13-
501		propeller a marker of emerging resistance to artemisinin among plasmodium
502		falciparum in Africa? Vol. 213, Journal of Infectious Diseases. Oxford University
503		Press; 2016. p. 165–6.
504	48.	Ndwiga L, Kimenyi KM, Wamae K, Osoti V, Akinyi M, Omedo I, et al. A review of
505		the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations
506		in Africa. Vol. 16, International Journal for Parasitology: Drugs and Drug Resistance.
507		2021.

508	49.	Ocan M.	. Ashaba FK	. Mwesig	gwa S.	Edgar K.	Kamva MR	. Nsoby	a SL.	Prevalence of	of
000			,	.,	\sim ,			,,	~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~ ~~		-

- 509 arps10, fd, pfmdr-2, pfcrt and pfkelch13 gene mutations in Plasmodium falciparum
- 510 parasite population in Uganda. PLoS One. 2022 May 1;17(5 May).
- 511 50. Hawkes M, Conroy AL, Opoka RO, Namasopo S, Zhong K, Conrad Liles W, et al.
- 512 Slow clearance of Plasmodium falciparum in severe pediatric malaria, Uganda, 2011–
- 513 2013. Emerg Infect Dis. 2015;21(7):1237–9.
- 514 51. Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A
- 515 Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms . New
- 516 England Journal of Medicine. 2016 Jun 23;374(25):2453–64.
- 517 52. Muwanguzi J, Henriques G, Sawa P, Bousema T, Sutherland CJ, Beshir KB. Lack of
- 518 K13 mutations in Plasmodium falciparum persisting after artemisinin combination

519 therapy treatment of Kenyan children. Malar J. 2016 Jan 22;15(1).

- 520 53. Ocan M, Bwanga F, Okeng A, Katabazi F, Kigozi E, Kyobe S, et al. Prevalence of
- 521 K13-propeller gene polymorphisms among Plasmodium falciparum parasites isolated
- 522 from adult symptomatic patients in northern Uganda. BMC Infect Dis. 2016;16(1):1–9.
- 523 54. Straimer J, Gandhi P, Renner KC, Schmitt EK. High Prevalence of Plasmodium
- 524 falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance
- 525 After Treatment With Artemether-Lumefantrine. Journal of Infectious Diseases. 2022

526 Apr 15;225(8):1411–4.

527